483
Regenerative Biologics Inc.Regenerative Biologics Inc. – FDA 483, Feb 6, 2020
Record Details
An FDA inspection of Regenerative Biologics Inc., a human tissue recovery firm in Gainesville, FL, revealed a significant deficiency in donor screening practices. The firm failed to adequately document and identify risk factors for communicable diseases, specifically Zika, in three birth tissue donors whose tissues were recovered from an area designated for active Zika transmission. This oversight indicates a failure to ensure donor eligibility and the safety of recovered tissues.
View Company Profile
ID · f915223d-6272-452e-91d7-89702485ffeb
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.